Sanofi (NASDAQ:SNY) Shares Sold by Fmr LLC

FMR LLC cut its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 42.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,963,221 shares of the company's stock after selling 3,654,396 shares during the period. FMR LLC owned approximately 0.20% of Sanofi worth $239,376,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Synergy Asset Management LLC purchased a new stake in shares of Sanofi during the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. raised its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the 4th quarter worth $31,000. Sunbelt Securities Inc. boosted its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after acquiring an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in Sanofi during the fourth quarter worth about $44,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 0.1 %

SNY traded down $0.04 during trading on Wednesday, hitting $50.56. The company's stock had a trading volume of 5,640,036 shares, compared to its average volume of 2,361,421. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The firm's 50 day moving average price is $54.89 and its 200-day moving average price is $52.30. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market cap of $127.73 billion, a PE ratio of 20.31, a PEG ratio of 1.01 and a beta of 0.57.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on SNY. BNP Paribas assumed coverage on Sanofi in a report on Tuesday. They issued an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.